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Chronic all ergic reacti onIn 1965, cases of allergic, anaphylactic, and anaphylactoid
reactions with acute myocardial infarction were ﬁrst published
[1]. A quarter century ago, Kounis and Zavras reported allergic
angina due to histamine-induced coronary artery spasm in 1991
[2]. Allergic angina can progress to acute myocardial infarction
which was named ‘‘allergic myocardial infarction’’. In 1995,
Constantinides reported the potential that ordinary allergic
reactions could induce coronary plaque disruptions [3]. Braunwald
noted that coronary artery spasm can be provoked by allergic
reactions with mediators such as histamine or leukotrienes acting
on coronary vascular smooth muscle in 1998 [4]. Allergic angina
and allergic myocardial infarction are referred to as ‘‘Kounis
syndrome’’ and cardiologists sometimes may encounter this
syndrome in the cardiac catheterization laboratory. Three variants
of Kounis syndrome have been described, as shown in Fig. 1. Type I
variant includes patients with normal or near normal coronary
arteries without predisposing factors for coronary artery disease in
whom the acute release of inﬂammatory mediators can induce
either coronary artery spasm without increase of cardiac enzymes
and troponins or coronary artery spasm progressing to acute
myocardial infarction with raised cardiac enzymes and troponins.
Type II variant includes patients with culprit but quiescent
preexisting atheromatous disease in whom the acute release of
inﬂammatory mediators can induce either coronary artery spasm
with normal cardiac enzymes and troponins or coronary artery
spasm together with plaque erosion or rupture manifesting as
acute myocardial infarction. Type III variant includes patients with
coronary artery stent thrombosis in whom aspirated thrombus
specimens stained with hematoxylin-eosin and Giemsa demon-
strate the presence of eosinophils and mast cells, respectively [5,6].
Anaphylaxis is a systemic, immediate hypersensitivity reaction
caused by rapid IgE-mediated release of mediators from mast cells
and basophils. Kounis syndrome is deﬁned as the occurrence of
acute coronary syndromes with conditions associated with mastDOI of original article: http://dx.doi.org/10.1016/j.jccase.2015.05.007
http://dx.doi.org/10.1016/j.jccase.2015.07.006
1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightcell degranulation, involving interrelated and interacting inﬂam-
matory cells, and including allergic or hypersensitivity and
anaphylactic or anaphylactoid insults. It is caused by inﬂammatory
mediators such as histamine, neutral protease, arachidonic acid
products, platelet activating factors, and a variety of cytokines and
chemokines released during the activation process. It is well
known that histamine acts through four different histamine
receptors all of which contribute to the severity of the allergic
myocardial damage. H1-histamine receptors mediate coronary
vasoconstriction and increase vascular permeability. H2-histamine
receptors mediate a minor degree of relaxation of the coronary
arteries and increase atrial rate and atrial and ventricular
contractility. The interaction of H1- and H2-receptor stimulation
mediates decreased diastolic pressure and increased pulse
pressure. Histamine binding to H1-receptors during anaphylaxis
stimulates endothelial cells to convert the amino acid L-arginine
into nitric oxide, a potent autocoid vasodilator. Enhanced nitric
oxide production decreases venous return, thus contributing to theFig. 1.
The classiﬁcation of Kounis syndrome.
CAD, coronary artery disease.
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tors have been identiﬁed on presynaptic terminals of the
sympathetic effector nerves that innervate the heart and the
systemic vasculature. These receptors have been found to inhibit
endogenous norepinephrine release which would be expected to
enhance the degree of shock during anaphylaxis events. H4-
histamine receptors control chemotaxis of murine mast cells and
human eosinophils and the release of interleukin-16 from human
lymphocytes. The recruitment of these speciﬁc inﬂammatory cells
at the sites of the allergic response correlates with the severity of
the allergic reaction [7].
In their paper, Kounis and Zavras reported the histamine-
induced coronary artery spasm [2]. Allergic angina is caused by
several chemical substances released during any immunologically
mediated reaction. Histamine is the most important of these
substances and has strong vasoconstrictive action mediated by H1-
receptors. Histamine induces coronary artery spasm with impaired
coronary perfusion and various electrocardiographic appearances.
In contrast, according to the report by Okumura et al., coronary
spasm was induced in 6 patients with histamine, in 18 with
acetylcholine and 1 with ergonovine in 21 patients with variant
angina [8]. Okumura et al. concluded that histamine induced
coronary spasm in some patients with variant angina by
stimulation of the H1 receptor of the coronary artery and it
caused coronary vasodilatation in the majority of patients,
especially those without advanced coronary artery disease,
presumably through release of the endothelium-derived relaxing
factor. Sakata et al. also reported that whereas histamine
concentration was elevated in the great cardiac vein in 8 of
11 patients suffering from attacks of variant angina, they did not
observe any histamine elevation during or after acetylcholine-
induced coronary artery spasm. While elevation of plasma
histamine levels was antecedent to angina attacks in 3 patients,
high levels of histamine were observed even in the absence of ST
segment elevation in the same group of patients [9]. Considering
these issues, allergic angina probably induced by histamine may be
a different state from variant angina. Although the phenomenon of
coronary vasoconstriction is the same response, Kounis syndrome
may be a different disease from variant angina.
In this case report, a 79-year-old man without allergic history
presented with an anaphylactic reaction complicated with
showing ST elevation in inferior leads when he had received
transcatheter arterial chemoembolization for treatment of hepa-
tocellular carcinoma at the sixth time. Emergency coronary
angiography did not reveal any organic stenosis nor occluded
lesions of the coronary arteries. Therefore, the author made
diagnosis of Kounis syndrome (Type I). Although Kounis syndrome
is a rare disease, physicians in the clinic should be aware of this
disease [10]. It is helpful for cardiologists to realize the presence of
Kounis syndrome in the real world. Cardiologists should treat both
anaphylactic shock and coronary artery spasm. In this report, all
three cases demonstrated ST elevation in inferior leads and the
author suggests that right coronary artery may be prone to be
affected by acute allergic insults more than left coronary artery. In
fact, Kounis syndrome should be considered in young, healthy
patients with no atherosclerotic risk factors when they develop
acute coronary syndrome, especially inferior myocardial infarc-
tion, after administration of potentially allergic agents [11]. Car-
diologists should suspect Kounis syndrome in young patients with
anaphylactic shock and inferior ST elevation.
Kounis syndrome is a category of coronary artery disease. Many
chemical mediators may concern the occurrence of Kounis
syndrome. Histamine may be the most important chemical
mediator but other factors, such as coronary atherosclerotic state
and general condition, may also contribute to the occurrence of
this syndrome. However, we cannot know the occurrence ofanaphylactic shock and coronary artery spasm before clinical use.
Just after the occurrence of Kounis syndrome, we realize this
phenomenon.
In the future, we may understand the relationship between
coronary spastic angina and Kounis syndrome (allergic angina and
allergic myocardial infarction) if we performed the spasm
provocation tests in some patients with Kounis syndrome
[12]. However, it may be difﬁcult to perform the spasm
provocation tests in these Kounis syndrome patients due to the
point of procedures or ethical problems. Patients with Kounis
syndrome have a good prognosis and a rare reoccurrence. Coronary
spastic angina also has a good prognosis under the optimal
medications including long-acting calcium channel antagonists.
However, Kounis syndrome (type I and type II) is a coronary artery
disease which may be remarkably different from coronary spastic
angina.
Kounis et al. described a series of eight patients (0.67–0.8%)
who had both allergic or anaphylactic reactions and acute coronary
syndromes as type II of Kounis syndrome in approximately 1000–
1200 patients with coronary care unit admissions [13]. They
performed six percutaneous coronary interventions and one
coronary aorta bypass graft surgery in 7 out of 8 all patients.
They noted that atherosclerotic plaques might rupture as a result
of the humoral effects of an allergic insult. In these patients,
allergic or anaphylactic reactions may be one of the triggers of
occurrence of acute coronary syndrome. However, it is controver-
sial whether all eight patients had plaque ruptures at the
atherosclerotic portions or not. They also mentioned that their
study could not constitute the sole proof of evidence for a cause
and effect relationship.
Kounis syndrome is classiﬁed into three types. While type I and
type II are acute allergic reactions, type III is considered as chronic
allergic reaction [14,15]. Kounis syndrome is well recognized as
acute allergic angina and acute allergic myocardial infarction.
Although chronic inﬂammation after the implantation of coronary
stents may lead to the occurrence of acute coronary syndrome, the
majority of cardiologists may have some reservations about the
deﬁnition of Kounis syndrome type III. Because original Kounis
syndrome was deﬁned as histamine-induced coronary spasm in
1991, physicians may have some difﬁculty to understand that
Kounis type III syndrome is related to late stent thrombosis after
the implantation of coronary stents. General cardiologists in the
real world may understand that Kounis syndrome is acute allergic
angina and acute allergic myocardial infarction.
As a therapy in patients with Kounis syndrome type I and type
II, it is necessary to manage acute coronary syndrome and
anaphylaxis. Most cases have been treated with steroids, H1-
blockers, nitroglycerin, H2-blockers, and epinephrine. The Kounis
syndrome type III, as a possible manifestation of hypersensitivity
to stent components or anti-platelet agents, might play a key role
in the mechanism of drug-eluting stent thrombosis. Recently,
some experimental studies have reported attenuation of allergic
and thrombotic events through treatment with corticosteroids and
other mast cell stabilizing agents. Although Kounis syndrome is a
rare phenomenon, cardiologists should investigate the relation-
ship between allergic reactions and coronary artery diseases in the
clinic in the future.
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